Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.55 |
| ▸ | ITGB3 known ✓ | P05106 | 1/20 | 0.55 |
| ▸ | ITGA2B known ✓ | P08514 | 1/20 | 0.55 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.55 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.55 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.53 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.69 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.55 |
| ▸ | HPGD | P15428 | 5/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.55 |
| ▸ | GGT1 | P19440 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1798 | 0.98 | CTNNB1 (0.71) | CTNNB1HTTALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL4129945 | 0.96 | CTNNB1 (0.69) | CTNNB1HTTALDH1A1SMN1; SMN2HSD17B10 | |
| Bicarbonate SCHEMBL29943548 | 0.96 | CTNNB1 (0.69) | CTNNB1HTTALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL17888702 | 0.96 | CTNNB1 (0.69) | CTNNB1HTTALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL8496446 | 0.96 | CTNNB1 (0.69) | CTNNB1HTTALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL11875755 | 0.96 | CTNNB1 (0.69) | CTNNB1HTTALDH1A1SMN1; SMN2HSD17B10 | |
| Bicarbonate SCHEMBL236889 | 0.96 | CTNNB1 (0.69) | CTNNB1HTTALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL11407865 | 0.96 | CTNNB1 (0.69) | CTNNB1HTTALDH1A1SMN1; SMN2HSD17B10 | |
| Bicarbonate SCHEMBL21517637 | 0.96 | CTNNB1 (0.69) | CTNNB1HTTALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL1537710 | 0.94 | HTT (0.70) | CTNNB1HTTALDH1A1SMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0030676-B1 | DERIVATIVES OF PHENOXYBENZOIC ACID, PROCESS FOR THEIR PREPARATION AND THEIR USE AS HERBICIDES AND AS PLANT GROWTH REGULATORS | BAYER AG (DE) | 1984-02-08 | — | — | EP | claimed |
| US-20180282336-A1 | Active Acrylamides | SANDOZ AG (CH) | 2018-10-04 | — | — | US | disclosed |
| US-20170327504-A1 | Synthesis of Substituted 1H-Pyrazolo[3,4-D]Pyrimidines | SANDOZ AG (CH) | 2017-11-16 | — | — | US | disclosed |
| EP-3212624-A1 | SYNTHESIS OF SUBSTITUTED 1H-PYRAZOLO[3,4-D]PYRIMIDINES | Sandoz AG (CH) | 2017-09-06 | — | — | EP | disclosed |
| EP-3212653-A2 | ACTIVE ACRYLAMIDES | Sandoz AG (CH) | 2017-09-06 | — | — | EP | disclosed |
| WO-2016066726-A2 | ACTIVE ACRYLAMIDES | SANDOZ AG (CH) | 2016-05-06 | — | — | WO | disclosed |
| WO-2016066673-A1 | SYNTHESIS OF SUBSTITUTED 1H-PYRAZOLO[3,4-D]PYRIMIDINES | SANDOZ AG (CH) | 2016-05-06 | — | — | WO | disclosed |
| EP-0904262-B1 | CONFORMATIONALLY RESTRICTED AROMATIC INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2004-04-21 | — | — | EP | disclosed |
| US-6472414-B1 | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-29 | — | — | US | disclosed |
| EP-0904262-A4 | CONFORMATIONALLY RESTRICTED AROMATIC INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2000-10-04 | — | — | EP | disclosed |
| US-5827875-A | PYRROLIDINE DERIVATIVES; ANTIATHEROSCLEROSIS AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-10-27 | — | — | US | disclosed |
| US-5760246-A | ANTILIPEMIC AGENTS, ANTICHOLESTEROL AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 1998-06-02 | — | — | US | disclosed |
| WO-1997043257-A1 | INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-11-20 | — | — | WO | disclosed |
| WO-1997026240-A1 | CONFORMATIONALLY RESTRICTED AROMATIC INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-07-24 | — | — | WO | disclosed |
| US-4889946-A | Phenoxybenzoic acid compounds and herbicidal and plant growth regulant compositions | BAYER AKTIENGESELLSCHAFT (DE) | 1989-12-26 | — | — | US | disclosed |
| US-4723985-A | Herbicidal phenoxybenzoic acid derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 1988-02-09 | — | — | US | disclosed |
| US-4540827-A | Phenoxybenzene derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 1985-09-10 | — | — | US | disclosed |
| US-4482736-A | Herbicidally active substituted phenoxycinnamic acid derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 1984-11-13 | — | — | US | disclosed |
| US-4435208-A | Herbicidally active substituted phenoxycinnamic acid derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 1984-03-06 | — | — | US | disclosed |
| EP-0070990-A2 | Substituted phenoxybenzoic acid-azolylalkyl esters, process for their preparation and their herbicidal application | BAYER AG (DE) | 1983-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282336-A1 | Active Acrylamides | BTK, SYK, LYN | ESR1 1694/4885ITGB3 1304/4885ITGA2B 1563/4885 |
| US-20170327504-A1 | Synthesis of Substituted 1H-Pyrazolo[3,4-D]Pyrimidines | BTK, ABL1, SYK | ESR1 2312/4885ITGB3 3467/4885ITGA2B 4061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.